AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

April 18, 2022 Shanghai, China——Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasd

Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System

Xiamen, China April 13, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Beckman Coulter Life Sciences, a global leader in life sciences lab automation and innovation, announce

AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China

Xiamen, China - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13), an innovative, commercial-stage, biopharmaceutical co

China's NMPA Granted Approval to AmoyDx^® PD-L1 Expression Detection Kit (IHC)

Xiamen, China, March 15, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that China’s National Medical Products Administration (NMPA) recently granted Approval to A

AmoyDx Collaborates with Pierre Fabre to Develop Companion Diagnostics for China Market

Xiamen (China), Castres (France), February 23rd, 2022 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), and the French pharmaceutical group Pierre Fabre announced that the companies have entered into a collaboration to develop Companion Diagnostic (CDx)

Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx^® Pan Lung Cancer PCR Panel

TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am

AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan

Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph

AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx^® Pan Lung Cancer PCR Panel in Japan

Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx^® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio

Amoy Diagnostics and Janssen China Sign MoU on Strategic Collaboration

Xiamen China, December 9, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) recently signed a Memorandum of Understanding (MoU) on strategic collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson. In this cooperation, both par

AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market

Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio

AmoyDx^® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO^® (tepotinib)

TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the

AmoyDx^® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx^® Pan Lung Cancer PCR Panel (the “AmoyDx^® PLC Panel”), an i

AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market

Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o

AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer

Xiamen, China, 19th February, 2021 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with AstraZeneca to develop a Homologous Recombination Deficiency (HRD) Companion Diagnostic (CDx) in ovarian cancer.

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market

Xiamen, China, December 23, 2020 (12:30 pm) – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepo

AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide

Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.

AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award

The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).

AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market

Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx